Chicago Partners Investment Group LLC grew its holdings in shares of Baxter International Inc (NYSE:BAX) by 31.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,351 shares of the medical instruments supplier’s stock after purchasing an additional 800 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Baxter International were worth $225,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. FMR LLC increased its holdings in Baxter International by 25.6% in the 2nd quarter. FMR LLC now owns 28,637,027 shares of the medical instruments supplier’s stock worth $2,114,558,000 after acquiring an additional 5,845,720 shares during the last quarter. Voya Investment Management LLC increased its holdings in Baxter International by 411.6% in the 2nd quarter. Voya Investment Management LLC now owns 3,411,849 shares of the medical instruments supplier’s stock worth $251,931,000 after acquiring an additional 2,745,012 shares during the last quarter. Morgan Stanley increased its holdings in Baxter International by 107.8% in the 2nd quarter. Morgan Stanley now owns 2,873,253 shares of the medical instruments supplier’s stock worth $212,161,000 after acquiring an additional 1,490,287 shares during the last quarter. Standard Life Aberdeen plc increased its holdings in Baxter International by 77.2% in the 2nd quarter. Standard Life Aberdeen plc now owns 2,596,870 shares of the medical instruments supplier’s stock worth $191,753,000 after acquiring an additional 1,131,691 shares during the last quarter. Finally, Swiss National Bank increased its holdings in Baxter International by 6.1% in the 2nd quarter. Swiss National Bank now owns 2,191,439 shares of the medical instruments supplier’s stock worth $161,816,000 after acquiring an additional 125,700 shares during the last quarter. 82.28% of the stock is owned by hedge funds and other institutional investors.

In other Baxter International news, SVP Giuseppe Accogli sold 17,647 shares of the firm’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $77.27, for a total value of $1,363,583.69. Following the completion of the transaction, the senior vice president now owns 59,452 shares in the company, valued at approximately $4,593,856.04. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.05% of the stock is owned by company insiders.

Shares of NYSE BAX opened at $63.48 on Friday. Baxter International Inc has a 52 week low of $61.05 and a 52 week high of $78.38. The company has a quick ratio of 2.00, a current ratio of 2.60 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $33.79 billion, a price-to-earnings ratio of 21.82, a P/E/G ratio of 1.71 and a beta of 1.02.

Baxter International (NYSE:BAX) last issued its earnings results on Wednesday, October 31st. The medical instruments supplier reported $0.80 EPS for the quarter, topping the consensus estimate of $0.74 by $0.06. Baxter International had a return on equity of 17.67% and a net margin of 10.90%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.79 billion. During the same quarter last year, the company earned $0.64 EPS. The firm’s revenue was up 2.2% compared to the same quarter last year. On average, equities analysts forecast that Baxter International Inc will post 3 earnings per share for the current fiscal year.

BAX has been the subject of several recent research reports. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $87.00 price objective for the company in a report on Tuesday, September 25th. Argus raised Baxter International from a “hold” rating to a “buy” rating and set a $70.00 price objective for the company in a report on Friday, November 2nd. Royal Bank of Canada reissued a “hold” rating and issued a $76.00 price objective on shares of Baxter International in a report on Friday, July 27th. ValuEngine lowered Baxter International from a “buy” rating to a “hold” rating in a report on Thursday, November 1st. Finally, Citigroup lifted their price objective on Baxter International from $74.00 to $76.00 and gave the stock a “neutral” rating in a report on Tuesday, July 31st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $75.25.

WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2018/11/10/baxter-international-inc-bax-shares-bought-by-chicago-partners-investment-group-llc.html.

Baxter International Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: What is the Rule of 72?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.